{"entity":{"id":"bomedemstat","kind":"drug","name":"Bomedemstat","aka":[],"tldr":"Bomedemstat is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for myeloproliferative neoplasms, with its target not yet stated publicly.","summary":"Bomedemstat (MK-3543, IMG-7289) is a small-molecule drug developed by Merck Sharp & Dohme. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06351631 (A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)), in myeloproliferative neoplasms. The largest, NCT06351631, plans to enrol 400 participants with primary completion expected 2034-12-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Bomedemstat","url":"https://clinicaltrials.gov/search?intr=MK-3543"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms","polycythaemia-vera","essential-thrombocythaemia"],"sections":[],"technologies":["lsd1-inhibitors"],"targets":[],"drugs":[],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06351631"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"MK-3543, IMG-7289","modality":"small molecule","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bomedemstat/","neighbours":{"cancer":[{"id":"essential-thrombocythaemia","kind":"cancer","name":"Essential thrombocythaemia (ET)","route":"/cancers/essential-thrombocythaemia/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/"}],"technology":[{"id":"lsd1-inhibitors","kind":"technology","name":"LSD1 inhibitors","route":"/technologies/lsd1-inhibitors/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"trial":[{"id":"nct06351631","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","route":"/trials/nct06351631/"}]}}